The Gastric Ulcers drugs in development market research report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gastric Ulcers. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for Gastric Ulcers by 17 companies/universities/institutes. The top development phase for Gastric Ulcers is phase i with ten drugs in that stage. The Gastric Ulcers pipeline has 18 drugs in development by companies and one by universities/ institutes. Some of the companies in the Gastric Ulcers pipeline products market are: Hanmi Pharmaceuticals, Jiangsu Carephar Pharmaceutical and Onconic Therapeutics.
The key targets in the Gastric Ulcers pipeline products market include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19), Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1), and Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1).
The key mechanisms of action in the Gastric Ulcers pipeline product include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19) Inhibitor with ten drugs in Pre-Registration. The Gastric Ulcers pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Gastric Ulcers pipeline products market including Small Molecule.
Gastric Ulcers overview
Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting, and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.
For a complete picture of Gastric Ulcers’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
